Clinical Trial Update: Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age [Phase 3]

View source ↗

Summary

Phase 3 trial assessing safety and immunogenicity of 20vPnC given with SIIV in adults aged 65 and older; study completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• 20vPnC (20-valent pneumococcal conjugate vaccine)
• SIIV (seasonal influenza vaccine)

Snippet

Sponsor: Pfizer | Conditions: Pneumococcal Disease | Phase 3 | Status: COMPLETED | Results posted: 2022-07-08